Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Fig. 4

a. Forest plots of the pooled RRs for the ORR, VGPR or better, VGPR, partial response, and stable disease of the patients with MM in the MAbs targeting CD38 group versus control group. The RR > 1 favours the MAb group. The size of the blocks or diamonds represents the weight of the random effects model in the meta-analysis. b Forest plots of the pooled RR for the complete response or better of the patients with MM in the MAbs targeting CD38 group versus control group. The RR > 1 favours the MAb group. The size of the blocks or diamonds represents the weight of the fixed effects model in the meta-analysis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us